Edition:
Deutschland

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,165JPY
23 May 2018
Change (% chg)

¥27 (+1.26%)
Prev Close
¥2,138
Open
¥2,151
Day's High
¥2,177
Day's Low
¥2,143
Volume
1,442,800
Avg. Vol
1,666,429
52-wk High
¥2,177
52-wk Low
¥1,397

4506.T

Chart for 4506.T

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Japan segment manufactures and sells ethical and general use drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other... (more)

Buy/Sell

Sell Hold Buy
3.56 Mean rating from 9 analysts

Overall

Beta: 0.76
Market Cap(Mil.): ¥604,410.31
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.18

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

BRIEF-Sumitomo Dainippon Pharma says change of president

* Says it appoints Masayo Tada as chairman of the board, and Hiroshi Nomura as president, effective April 1

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

BRIEF-Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.

* Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC regarding their submissions of Abbreviated New Drug Applications for generic copies of LATUDA®(lurasidone HCl tablets)

BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film

* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes)

BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan

* POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN

BRIEF-Sumitomo Dainippon Pharma says result of early-retirement program

* Says 86 employees took up the offer of the early-retirement program announced on Sept. 27

BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD

* SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -1.01%
Rohstoffe -0.41%
Industrie -0.14%
Konjunktur abhängige Waren & Dienstleistungen +0.32%
Konjunktur unabhängige Waren & Dienstleistungen -0.57%
Finanzindustrie +0.11%
Pharma +0.74%
Technologie -0.31%
Telekommunikation +0.41%

Nachrichten aus der Wirtschaft

Photo

US-Industrie mit weniger Aufträgen

Washington Überraschend starker Auftragsschwund in der US-Industrie: Die Bestellungen für langlebige Güter - vom Toaster bis zum Flugzeug - fielen im April um 1,7 Prozent zum Vormonat, wie das Handelsministerium am Freitag in Washington mitteilte.